Streetbeat News

Stock Prices

NUTX

Nutex Health shares are trading higher after the company reported better-than-expected Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 5:43 pm

ITRM

Iterum Therapeutics shares are trading higher following the announcement that the company will receive $7.4M in gross proceeds from the expiration and results of its rights offering.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 5:42 pm

DAT

FIVN

Five9, Inc. (NASDAQ:FIVN) shares are trading lower due to a revenue guidance cut for 2024, despite beating Q2 revenue and EPS estimates. Analysts have lowered price targets but maintain positive ratings, citing potential profitability and AI benefits. ProShares Big Data Refiners ETF (NYSE:DAT) offers exposure to FIVN.

Portfolio Pulse from Lekha Gupta

August 09, 2024 | 5:39 pm

GNS

Genius Group shares are trading higher following the announcement that the company's board has approved the purchase of up to 10 million shares by founder and CEO Roger James Hamilton.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 5:37 pm

BTMD

Biote shares are trading lower after the company reported worse-than-expected Q2 EPS results.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 5:35 pm

GNS

Genius Group shares have resumed trading after a temporary halt. This development is significant for investors as it may impact the stock's short-term price movements.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 5:35 pm

AAP

AMZN

BKNG

CAVA

GM

HLT

NKE

RCL

SG

TSLA

The article highlights significant options activity in the Consumer Discretionary sector, focusing on trades involving companies like TSLA, NKE, RCL, SG, GM, AMZN, AAP, CAVA, HLT, and BKNG. These activities include both bullish and bearish sentiments, with varying expiration dates and strike prices.

Portfolio Pulse from Benzinga Insights

August 09, 2024 | 5:35 pm

GNS

Genius Group (GNS) shares have been halted pending news. Investors are awaiting further information.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 5:35 pm

SNY

SPRY

The FDA has approved ARS Pharmaceuticals Inc's (NASDAQ: SPRY) Neffy nasal spray for emergency allergy treatment, providing an alternative to EpiPen and other autoinjectors like Sanofi SA's (NASDAQ: SNY) Auvi-Q. This approval comes ahead of the PDUFA target action date and is based on studies showing comparable efficacy to existing epinephrine injection products.

Portfolio Pulse from Vandana Singh

August 09, 2024 | 5:34 pm

RCAT

Red Cat Holdings shares are trading higher following the company's Q4 financial results announcement.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 5:34 pm